Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cell Culture Centre, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Nutrition. 2021 May;85:111135. doi: 10.1016/j.nut.2020.111135. Epub 2021 Jan 5.
The influence of body composition on clinical outcomes in individuals with gastric cancer (GC) undergoing radical gastrectomy after neoadjuvant treatment (NT) remains unclear. The purpose of this retrospective study was to investigate the association between body composition before NT or after NT and clinical outcomes in individuals with GC receiving multimodal treatments.
This retrospective study included individuals with GC who received NT followed by radical gastrectomy between January 2016 and December 2018. Skeletal muscle, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were measured by cross-sectional areas at the level of third lumbar vertebra based on single-slice computed tomography scan prior to NT and prior to the surgical operation. Sarcopenia, high VAT, and high SAT were defined using cutoff points of skeletal muscle index, visceral fat area, and subcutaneous fat area. Univariate and multivariate analyses were performed to evaluate risk factors of NT-related adverse events, postoperative complications and predictors of long-term survival.
A total of 110 individuals with GC were enrolled in this study. Sarcopenia was present in 62.7% of them before NT and in 56.4% after NT. Sarcopenia before NT was associated with more NT-related adverse events (odds ratio, 2.901; 95% confidence interval [CI], 1.205-6.983; P = 0.018). High VAT after NT (≥106 cm) was associated with an increasing incidence of postoperative complications (odds ratio, 4.261; 95% CI, 1.332-13.632; P = 0.015). No body-composition parameter was relevant to tumor pathologic response to NT. As for long-term survival, poor overall survival was associated with both low VAT before NT (<120 cm; hazard ratio [HR], 2.542; 95% CI, 1.111-5.817; P = 0.027) and low SAT after NT (<99.5 cm; HR, 2.743; 95% CI, 1.248-6.027; P = 0.012). Similarly, shorter disease-free survival was associated with low VAT before NT (<120 cm; HR, 2.502; 95% CI, 1.222-5.124; P = 0.012) and low VAT after NT (<106 cm; HR, 2.505; 95% CI, 1.172-5.358; P = 0.018).
Body composition measured by computed tomography could predict NT-related adverse events, postoperative complications, and long-term survival in multimodal treatments for GC. More meaningfully, adipose-tissue status has significant prognostic value for individuals with advanced GC.
新辅助治疗(NT)后行根治性胃切除术的胃癌(GC)患者的体成分对临床结局的影响尚不清楚。本回顾性研究的目的是探讨 NT 前后体成分与接受多模式治疗的 GC 患者临床结局之间的关系。
本回顾性研究纳入了 2016 年 1 月至 2018 年 12 月期间接受 NT 后行根治性胃切除术的 GC 患者。在 NT 前和手术前,通过第三腰椎水平的单层面计算机断层扫描测量骨骼肌、内脏脂肪组织(VAT)和皮下脂肪组织(SAT)的横截面积。采用骨骼肌指数、内脏脂肪面积和皮下脂肪面积的截断点定义肌少症、高 VAT 和高 SAT。进行单因素和多因素分析,以评估 NT 相关不良事件、术后并发症的危险因素和长期生存的预测因素。
本研究共纳入 110 例 GC 患者。他们中有 62.7%的人在 NT 前存在肌少症,56.4%的人在 NT 后存在肌少症。NT 前的肌少症与更多的 NT 相关不良事件相关(优势比,2.901;95%置信区间[CI],1.205-6.983;P=0.018)。NT 后高 VAT(≥106cm)与术后并发症发生率的增加相关(优势比,4.261;95%CI,1.332-13.632;P=0.015)。没有体成分参数与 NT 对肿瘤病理反应相关。至于长期生存,总生存不良与 NT 前低 VAT(<120cm;风险比[HR],2.542;95%CI,1.111-5.817;P=0.027)和 NT 后低 SAT(<99.5cm;HR,2.743;95%CI,1.248-6.027;P=0.012)均相关。同样,较短的无病生存与 NT 前低 VAT(<120cm;HR,2.502;95%CI,1.222-5.124;P=0.012)和 NT 后低 VAT(<106cm;HR,2.505;95%CI,1.172-5.358;P=0.018)均相关。
CT 测量的体成分可预测 GC 多模式治疗中的 NT 相关不良事件、术后并发症和长期生存。更有意义的是,脂肪组织状态对晚期 GC 患者具有显著的预后价值。